Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bridging studies

B Fritzell1

  • 1Chiron Vaccines Clinical Research, Amsterdam, The Netherlands.

Developments in Biological Standardization
|December 17, 1998
PubMed
Summary
This summary is machine-generated.

Bridging studies can avoid repeating large vaccine trials by extrapolating efficacy data. These studies demonstrate equivalent immunogenicity, ensuring vaccine effectiveness across diverse populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Report of the 2nd "French Clinical Vaccinology Meeting Jean-Gerard Guillet": immunization and respiratory diseases.

Vaccine·2010
Same author

Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France.

Vaccine·2009
Same author

Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Epidemiology and infection·2006
Same author

Detection of adverse events: what are the current sensitivity limits during clinical development?

Vaccine·2001
Same author

Safety and immunogenicity of Haemophilus influenzae type b-tetanus toxoid conjugate, presented in a dual-chamber syringe with diphtheria-tetanus-pertussis and inactivated poliomyelitis combination vaccine.

European journal of pediatrics·1999
Same author

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.

Vaccine·1999

Area of Science:

  • Vaccinology
  • Clinical Trials
  • Immunology

Background:

  • Large-scale vaccine efficacy trials are resource-intensive.
  • Generalizing vaccine efficacy to new populations often requires additional studies.
  • Bridging studies offer a potential method to avoid duplicative efficacy trials.

Purpose of the Study:

  • To explore the utility of bridging studies in vaccine development.
  • To define the role of immunogenicity data in extrapolating vaccine efficacy.
  • To identify factors influencing vaccine efficacy and the decision to conduct bridging studies.

Main Methods:

  • Reviewing previous experiences with vaccine bridging studies.
  • Analyzing the correlation between immune response and vaccine-induced immunity.

Related Experiment Videos

  • Assessing ethnic and vaccine-related factors impacting vaccine efficacy.
  • Defining bridging studies as trials to demonstrate equivalent immunogenicity.

    • Main Results:

    • Bridging studies can avoid the need for large-scale efficacy trials in new populations.
    • Immunogenicity data can be used to extrapolate efficacy when a correlate of protection exists.
    • The absence of a correlate of protection makes the bridging process more complex.
    • Identifying factors influencing efficacy is critical for deciding on bridging studies.

    Conclusions:

    • Bridging studies are essential for demonstrating equivalent immunogenicity across populations.
    • Careful consideration of influencing factors is necessary for successful vaccine efficacy extrapolation.
    • Bridging studies streamline vaccine development by leveraging existing efficacy data.